



PRESS RELEASE
FOR IMMEDIATE DISTRIBUTION

Contact: Lauren Lamp, PLUG Public Relations
214.793.2299; lauren@plugpublicrelations.com

GeneIQ Partners with Texas Woman's University to Provide Weekly, On-site COVID-19 Testing to Unvaccinated Students, Faculty, Staff
Local Laboratory Continues to Offer On-site COVID-19 Services to Organizations and Facilities Amidst the Continuing Spread of the Delta Variant

DALLAS, TX (September 22, 2021) – **GeneIQ**, a molecular diagnostics company based in Dallas, has partnered with **Texas Woman's University (TWU)** to provide **weekly COVID-19 testing mandatory to enrolled unvaccinated students, faculty and staff on all three campuses** amidst a rise in Delta variant cases.

The new testing program has been introduced in support of the school's effort to mitigate the spread of COVID-19 on campus. COVID-19 testing is being provided at no cost to TWU students and employees, regardless of vaccination status. The rapid antigen tests are non-invasive and provided on-site at all three campuses – Denton, Dallas and Houston.

Weekly testing appointments can be scheduled online, and each appointment lasts 15 minutes while the recipient awaits the results of the test. Negative test results are documented per individual for each calendar week, and positive test results will result in the performance of a free PCR test to confirm the results of the rapid test. All positive rapid tests will be reported and documented. If the subsequent PCR test results are positive, the individual will be contact traced and required to isolate for ten days.

Exemptions to the testing requirement include:

- Non-residential students exclusively enrolled in 100% online courses or who don't come to TWU's campuses (such as student teachers)
- Dual credit students who do not come to the TWU campus
- Employees who fully telecommute
- Students and faculty/staff who submit proof of vaccination
- Student/faculty/staff with positive COVID-19 test within the last 90 days that has been reported via the COVID-19 form

To find out more about GenelQ and its other diagnostic offerings, visit [GenelQ's website](#). To learn more about testing options for your company or campus, please call 972-942-0110 or email vaccine@geneqlab.com.

About GenelQ

GenelQ is a high-volume, molecular diagnostics laboratory specializing in Pharmacogenomic (PGx) testing and real-time, reverse transcriptase polymerase chain reaction (RT-PCR) testing for urinary and respiratory infections, including COVID-19. The state-of-the-art laboratory based in the Dallas area services over 500 long-term care facilities, physician practices, state and local governments, corporations, and organizations throughout the United States. They have created a highly efficient, automated lab process with a paperless, web-based system that provides a 24-hour turnaround time of results after receiving the specimen. At the core of GenelQ lies the latest innovations in Pharmacogenomics, the science of determining how genetic variability influences physiological responses to drugs, from absorption and metabolism to pharmacologic action and therapeutic effect. In an effort to provide precision medicine and to serve the needs of the pandemic with molecular accuracy, the support and management teams at GenelQ are passionate about providing the highest level of service to their clients and the overall healthcare industry.

###